Clinical Trial

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.

Name: A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. — clinical trial record (NCT07539233)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019B in patients with relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07539233
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma (MM)
Enrollment	24 participants
Start Date	2026-04-15
Primary Completion	2028-08-01 (estimated)
Study Completion	2029-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-20